Gene · 5142
Papers1,785
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 1,785
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The LPAR1 antagonist, PIPE-791 produces antifibrotic effects in models of lung fibrosis. | Respir Res | 2025 | 40887574 | PubTator, text mining | PubMed |
| Pathophysiological Insights and Clinical Management Strategies for Interstitial Lung Diseases. | Biomol Ther (Seoul) | 2025 | 40803754 | PubTator, text mining | PubMed |
| Unmet needs and emerging pharmacotherapies for autoimmune connective tissue disease-associated interstitial lung diseases. | Autoimmun Rev | 2025 | 40769405 | PubTator, text mining | PubMed |
| Integrative network pharmacology and multi-omics reveal anisodamine hydrobromide's multi-target mechanisms in sepsis. | Sci Rep | 2025 | 40744980 | PubTator, text mining | PubMed |
| PDE4B Inhibition: Exploring the Landscape of Chemistry Behind Specific PDE4B Inhibitors, Drug Design, and Discovery. | Arch Pharm (Weinheim) | 2025 | 40654275 | PubTator, text mining | PubMed |
| Transcriptome profiling reveals major structural genes, transcription factors and biosynthetic pathways in refractory epilepsy in tropical region of China. | BMC Neurol | 2025 | 40646440 | PubTator, text mining | PubMed |
| New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025. | RMD Open | 2025 | 40592721 | PubTator, text mining | PubMed |
| G0S2: a potential target for NSCLC identified through prognostic models from multi-Omic analysis of regulatory T cell metabolic genes. | NPJ Precis Oncol | 2025 | 40537497 | PubTator, text mining | PubMed |
| Nerandomilast in Patients with Progressive Pulmonary Fibrosis. | N Engl J Med | 2025 | 40388329 | PubTator, text mining | PubMed |
| Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. | N Engl J Med | 2025 | 40387033 | PubTator, text mining | PubMed |
| Novel Azaindole Compounds as Phosphodiesterase 4B Inhibitors for Treating Immune-Inflammatory Diseases or Disorders. | ACS Med Chem Lett | 2025 | 40365387 | PubTator, text mining | PubMed |
| Comprehensive computational strategies for multi-target drug discovery in inflammatory bowel disease utilizing bioactive compounds. | Sci Rep | 2025 | 40319156 | PubTator, text mining | PubMed |
| Dialkyloxyphenyl hybrids as PDE4B inhibitors: Design, synthesis, in vitro/in vivo anti-inflammatory activity and in silico insights. | Bioorg Chem | 2025 | 40311245 | PubTator, text mining | PubMed |
| Discovering governing equations of biological systems through representation learning and sparse model discovery. | NAR Genom Bioinform | 2025 | 40290314 | PubTator, text mining | PubMed |
| Knockdown TNF family prognosis index crucial gene PDE4B promoted PANoptosis of ovarian carcinoma cell:Based in vitro and in vivo experiments. | Transl Oncol | 2025 | 40245751 | PubTator, text mining | PubMed |
| Insights into the Cellular and Molecular Mechanisms behind the Antifibrotic Effects of Nerandomilast. | Am J Respir Cell Mol Biol | 2025 | 40239038 | PubTator, text mining | PubMed |
| Role of PDE4 Family in Cardiomyocyte Physiology and Heart Failure. | Cells | 2025 | 40136709 | PubTator, text mining | PubMed |
| PDE4D inhibition ameliorates cardiac hypertrophy and heart failure by activating mitophagy. | Redox Biol | 2025 | 40015131 | PubTator, text mining | PubMed |
| Novel application of cycloastragenol target microglia for the treatment of Alzheimer's disease: Evidence from single-cell analysis, network pharmacology and experimental assessment. | Phytomedicine | 2025 | 39970860 | PubTator, text mining | PubMed |
| Rutaecarpine alleviates hepatic ischemia‒reperfusion injury in liver transplantation by inhibiting inflammatory response and oxidative stress. | Front Pharmacol | 2025 | 39963247 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5142/papers?page=5